Earnings season begins again, while big readouts loom for ALX and Fibrogen.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

The EU recommendation for odronextamab comes after a US rejection in March.

Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.

But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.

Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.